Clinical Rheumatology

, Volume 30, Issue 9, pp 1241–1245 | Cite as

Long-term follow-up of different refractory systemic vasculitides treated with rituximab

Brief Report


There is increasing interest in rituximab (RTX) as an alternative to cyclophosphamide (CYC) for remission induction in systemic vasculitis. Recent studies have reported high remission rates, but it is not clear how long the initial remission lasts [1, 2]. A retrospective study was undertaken of 15 cases of refractory systemic vasculitis (11 Wegener's granulomatosis, 1 Churg–Strauss syndrome, 1 cutaneous polyarteritis nodosa and 2 cryoglobulinaemic vasculitis) treated with RTX, with a mean follow-up of 34 months. All had previously received CYC, and 14, at least one other immunosuppressive drug. All had active disease when treated (median Birmingham Vasculitis Activity Score (BVAS) 2003, 13). All cases achieved remission (BVAS 2003, 0). Thirteen required re-treatment, nine due to relapse (mean, 9 months after initial treatment) and four because of repopulation or rising ANCA in the context of CYC intolerance or previous CYC refractory disease. Relapsing cases have been successfully re-treated up to five further cycles, either at B cell repopulation or at six monthly intervals. Infections were rare. Mean IgG levels fell significantly, and IgM levels became subnormal in six cases. There were three cases of neutropenia, one severe at 10 months post-treatment. These results provide further evidence that RTX is an effective induction agent in systemic vasculitis. The optimal and long-term outcome of re-treatment remains to be defined.


Refractory Relapse Rituximab Vasculitis 









  1. 1.
    Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173:180–187PubMedCrossRefGoogle Scholar
  2. 2.
    Keogh K, Wylam M, Stone J, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven cases with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52(1):262–268PubMedCrossRefGoogle Scholar
  3. 3.
    Stone J, Merkel P, Spiera R, Seo P, Langford C et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232PubMedCrossRefGoogle Scholar
  4. 4.
    Jones R, Cohen Tervaert J, Hauser T, Luqmani R, Morgan M, Peh C et al (2010) The European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220PubMedCrossRefGoogle Scholar
  5. 5.
    Lovric S, Erdbruegger U, Kumpers P et al (2009) Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 cases. Nephrol Dial Transplant 24:179–185PubMedCrossRefGoogle Scholar
  6. 6.
    Jones RB, Ferraro AJ, Chaudhry et al (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60(7):2156–2168PubMedCrossRefGoogle Scholar
  7. 7.
    Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D (2006) Long term observation of cases with anti-neutophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 45(11):1432–1436PubMedCrossRefGoogle Scholar
  8. 8.
    Aries PM, Hellmich B, Voswinkel J, Both M, Noelle B, Holl-Ulrich K et al (2006) Lack of efficacy of Rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853–858PubMedCrossRefGoogle Scholar
  9. 9.
    Martinez Del Pero M, Chaudhry A, Jones R, Sivasothy P, Jani P, Jayne D (2009) B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 34:328–335PubMedCrossRefGoogle Scholar
  10. 10.
    Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata N et al (2007) Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 46(7):409–414PubMedCrossRefGoogle Scholar
  11. 11.
    Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257(6):540–548PubMedCrossRefGoogle Scholar
  12. 12.
    Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL (2009) Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 60(5):1540–1547PubMedCrossRefGoogle Scholar
  13. 13.
    Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMedCrossRefGoogle Scholar
  14. 14.
    Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R (2007) Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66(3):283–292PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2011

Authors and Affiliations

  1. 1.Nottingham University Hospitals NHS TrustNottinghamUK

Personalised recommendations